TNFRSF17 and Miyoshi myopathy: Hence, an anti-BCMA ADC—belantamab mafodotin (GSK2857916)—has demonstrated meaningful single-agent activity in phase II of DREAMM-2 study for heavily pre-treated patients with RR MM, leading to its approval as monotherapy by the FDA and EMA [122,123].